Wed, 18 Jul 2018 08:09:00 +0100
Scancell Holdings inks drug delivery technology deal
It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
Tue, 17 Jul 2018 12:45:00 +0100
Clinigen unveils latest addition to medicine cabinet and says trading was in line with market forecasts
In an update, the speciality pharma company told investors it was acquiring the global rights to Proleukin for an undisclosed sum from Novartis
Tue, 17 Jul 2018 09:20:00 +0100
ValiRx advances as it wins patent protection pre-clinical drug to treat endometriosis
The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus
Mon, 16 Jul 2018 12:04:00 +0100
MaxCyte gears up for first clinical trial after gaining regulatory green light
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours
Fri, 13 Jul 2018 11:42:00 +0100
Ananda positions itself for medicinal cannabis revolution
Jeremy Sturges-Smith explains plans for Nex-listed company
Fri, 13 Jul 2018 11:26:00 +0100
Alliance Pharma building a head of steam in Asia Pacific
Alliance is continuing to build significant growth drivers into its business, Numis Securities asserts. The company's house broker is forecasting 10% revenue growth from 2018 to 2020
Thu, 12 Jul 2018 07:59:00 +0100
ReNeuron Group well funded for the next phase of development
The cell therapy specialist also reported there had been industry interest around its main programmes
Wed, 11 Jul 2018 12:10:00 +0100
ReNeuron stands to net an initial US$5mln as US company runs rule over its retinal stem cell technology
It has inked a three-month exclusivity deal with an unnamed American speciality pharma group
Tue, 10 Jul 2018 12:37:00 +0100
Summit Therapeutics receives grant to further its development of a treatment for gonorrhoea
Summit has identified a series of new mechanism antibiotic compounds that have shown high potency against a range of Neisseria gonorrhoea strains, including those that were multi-drug resistant
Thu, 28 Jun 2018 14:36:00 +0100
Mereo honing its expertise in brittle bones, endocrine and respiratory diseases
For an AIM company, Mereo BioPharma Group has a pipeline more akin to those of a pharma major. Indeed, big names such as Novartis and AstraZeneca have small stakes in its drug development programmes
Thu, 28 Jun 2018 13:35:00 +0100
Walgreens 3Q earnings beat on revenue surge; announces US$10bn buyback
The drugstore chain is also raising its dividend by 10%
Thu, 28 Jun 2018 12:14:00 +0100
Rapid Nutrition’s deal with major US nutrition supplement retailer GNC is a harbinger of greater things to come
Rapid Nutrition is tapping into a potentially huge market
Thu, 28 Jun 2018 07:31:00 +0100
Faron Pharmaceuticals to file clinical trial application for Clevegen after successful study
“We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen," said Faron Pharmaceuticals chief executive Dr Markku Jalkanen
Mon, 25 Jun 2018 11:36:00 +0100
UBS reckons Tagrisso will be worth more than US$5bn a year to AstraZeneca by 2022
Tagrisso sales look like they will beat expectations over the coming years, but UBS has concerns that the future profits drag brought about by externalisation deals hasn’t been properly factored into estimates yet
Thu, 21 Jun 2018 07:30:00 +0100
Silence Therapeutics strengthens the business with two key appointments
The drug developer has drafted in a new director as well as recruiting a head of clinical development
Tue, 19 Jun 2018 14:50:00 +0100
Alliance Pharma makes
Tue, 19 Jun 2018 08:04:00 +0100
InnovaDerma chairman hails strong revenue growth; bottom line hit by one-off investments and supply chain issue
The owner of the hugely successful Skinny Tan brand said the company's direct to consumer platform had been "key to driving sales"
Mon, 18 Jun 2018 10:16:00 +0100
Indivior wins temporary legal respite as competitor is prevented by court from launching cheap copycat product
The restraining order, handed down by the US District Court for the District of New Jersey, will remain in place pending a hearing on the preliminary injunction motion filed by Indivior last Friday
Sun, 17 Jun 2018 07:00:00 +0100
Licensing deals are the life blood for UK drug developers
The act of securing of licensing deals and partnerships is such an important value inflexion point for smaller drug developers it warrants a more detailed write up of its own
Sat, 16 Jun 2018 11:00:00 +0100
How to invest in pharma stocks: Make the most of inflection points and event driven trading
Navigating clinical trial processes is of course central to any investment thesis in the drug development sector, but, there' plenty more to consider in this sector
Thu, 14 Jun 2018 07:34:00 +0100
Faron Pharmaceuticals garners some encouragement from phase III data; still searching for answers to key questions
It has discovered that a sub-group of patients with higher levels of certain bio-markers showed a reduced mortality rate and increased ventilator-free days
Wed, 13 Jun 2018 07:42:00 +0100
Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"
The company's flagship product is a fast-acting gel for erectile dysfunction
Wed, 13 Jun 2018 07:19:00 +0100
Flying Brands subsidiary Imaging Biometrics inks neuroscience research partnership
Its software will be loaded to a cloud-based platform called QMENTA
Mon, 11 Jun 2018 09:05:00 +0100
MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease
The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH
Sat, 09 Jun 2018 11:00:00 +0100
Here’s how you should be valuing drug companies
Drug company valuations are largely made using a discounted cash flow model but it is far from a perfect system
Fri, 08 Jun 2018 07:35:00 +0100
Midatech Pharma gets key clinical trial underway for cancer product
The US phase IV study will assess Gelclair's use in patients undergoing stem cell transplant therapy
Thu, 07 Jun 2018 14:31:00 +0100
Alliance Pharma gets boost as morning sickness drug gets UK regulatory green light
Chief executive Peter Butterfield said: "We are delighted by this news and look forward to launching Diclectin later this year."
Thu, 07 Jun 2018 08:06:00 +0100
NeuroproteXeon plans AIM float to fund technology that may offer hope to cardiac arrest patients with complications
Proceeds of from the public offering of new stock will be used to bankroll a phase III clinical trial of XENEX, used to deliver pharmaceutical-grade xenon gas
Wed, 06 Jun 2018 07:27:00 +0100
Instem lands US$750,000 contract with Fortune 500 giant
The unnamed medical products and pharma company has adopted Instem's Samarind Regulatory Management System
Mon, 04 Jun 2018 15:43:00 +0100
Abzena shares gain as biotech firm says year just gone was a period of transition
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Fri, 13 Jul 2018 08:43:00 +0100
Ananda Developments 'building strong relationships in the medicinal cannabis space'
' Jeremy Sturgess-Smith visited the Proactive Investors studio a week after the company begun trading on the NEX exchange in London.
Sturgess-Smith says their strategy's to invest in companies, projects or products that are either progressing medicinal or therapeutic Cannabis research and development or ones that have already developed products and require funding.
He adds they're looking to invest in companies or projects in Israel, Canada and the Netherlands.
Wed, 21 Feb 2018 12:14:00 +0000
A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2
Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (), caught up with Proactive following their
Wed, 06 Sep 2017 12:54:00 +0100
Faron Pharmaceuticals boss upbeat as Phase III trial enters critical period
Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd () tells Proactive's Andrew Scott they're entering an exciting period for the company with recruitment for their Phase III trial for its lead drug set for completion later this year.
A positive readout for Traumakine, which is used to treat acute respiratory distress syndrome caused by pneumonia, would pave the way for its launch in Europe and the US.
Clevegen, Faron’s cancer immunotherapy, is set to undergo preclinical toxicity studies.
Tue, 18 Apr 2017 13:22:00 +0100
Faron Pharmaceuticals' Markku Jalkanen 'excited' to be advancing Clevegen
Markku Jalkanen, chief executive of clinical stage biopharma group () tells Proactive he's hugely excited to be teaming up with the University of Birmingham as they look to advance their potential cancer immunotherapy, Clevegen.
Wed, 29 Mar 2017 15:59:00 +0100
'This year will give us the results we've been waiting for', says Faron pharmaceuticals boss
Faron Pharmaceuticals Ltd () CEO Dr Markku Jalkanen caught up with Proactive to run through the company's 2016 results and outlook for the year ahead.
Traumakine, used to treat acute respiratory distress syndrome, is undergoing a phase III clinical trial with results expected in the second half.
Traumakine is now being developed for a second indication, a condition called rupture of abdominal aorta aneurysm.
Thu, 09 Feb 2017 11:36:00 +0000
Faron Pharmaceuticals to build on success of 'extremely exciting' 2016
Dr Markku Jalkanen, chief executive,
Thu, 02 Feb 2017 12:54:00 +0000
Rainmaker Resources has an early stage project in hot commodity lithium
Chris Healey, chief executive at Toronto-listed
Mon, 31 Oct 2016 13:23:00 +0000
Faron Pharmaceuticals boss says patent protection is very significant step
() chief executive Dr Markku Jalkanen says securing patent protection is a very significant step for the company.
“This is the very first ever granted claims to protect intravenous use of interferon-beta,” he highlighted in a Proactive Investors interview.
The drug developer now intends to transpose the patent protections in Finland across some 150 countries covered by international co-operation arrangements, and it will separately file into the US patents office.
“So this was the very initial filing and we are really happy that we got the claims accepted and it is a very significant step for us.”
Wed, 28 Sep 2016 11:01:00 +0100
Faron Pharmaceuticals Oy’s options widen after fund-raising
Demand for shares in ’s () was strong when the company tapped the City last week for
Tue, 06 Sep 2016 15:25:00 +0100
Faron Pharmaceuticals Oy boss pleased with healthier than expected cash balance
() ended the first half of 2016 with more cash than it had anticipated.
Research & development (R&D) expenses more than doubled, but the combination of higher than anticipated income, in the form of both revenue and grant income, and lower operating costs meant the company experienced only a modest cash outflow over the reporting period.
Chief executive Dr Markku Jalkanen told Proactive revenue comprised mostly of a ˆ750,000 signing fee from Pharmbio and a ˆ356,500 pre-payment relating to IFB-beta production.
The group also received ˆ968,000 from the European Union from its FP7 Traumakine grant.
The company had a cash balance of ˆ8.9mln at the end of June, it revealed in its results for the first half of the year.
Wed, 29 Jun 2016 12:46:00 +0100
Faron Pharmaceuticals drug has ‘tremendous potential’ following Korea deal, says CEO
Finland-based clinical stage drug discovery company Faron Pharmaceuticals () says there is “tremendous expansion potential” following the latest licensing deal with a Korean pharmaceuticals firm.
The group’s treatment for Acute Respiratory Distress Syndrome, Traumakine is on track to be the very first pharmacological treatment for this serious condition, explains chief executive Markku Jalkanen.
“The disease is very deadly, death usually occurs in 30-45% of patients,” says Jalkanen. The treatment is already in phase III trials in Europe and licences have been picked up by three companies in Asia, including the deal with Korean firm Pharmbio.
Speaking of the potential licences in its three major areas, including immunotherapy, chronic infection and vaccination, Jalkanen says that “if successful they will last for twenty years from now, so it’s a long term business opportunity for anyone utilising these technologies.”
Tue, 19 Apr 2016 11:03:00 +0100
Faron Pharma chief hopes for global patent protection for Clevegen
Markku Jalkanen, chief executive of
Wed, 03 Feb 2016 09:02:00 +0000
Faron Pharmaceuticals boss talks Traumakine and recent listing on AIM
Finland-based () has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage with its most promising product – Traumakine – a late stage product for acute respiratory distress syndrome.
Speaking to Proactive, chief executive Markku Jalkanen said the treatment, currently in Phase III trials in Europe, would be the first non-mechanical treatment for ARDS in the world.
The firm listed on AIM in November raising
view page: 38